Compare BC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BC | EWTX |
|---|---|---|
| Founded | 1845 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.3B |
| IPO Year | 1994 | 2021 |
| Metric | BC | EWTX |
|---|---|---|
| Price | $76.09 | $46.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 13 |
| Target Price | ★ $88.06 | $55.42 |
| AVG Volume (30 Days) | 824.4K | ★ 1.6M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.93 | ★ 8.86 |
| Revenue | ★ $5,362,800,000.00 | N/A |
| Revenue This Year | $7.41 | N/A |
| Revenue Next Year | $5.56 | N/A |
| P/E Ratio | $26.09 | ★ $5.19 |
| Revenue Growth | ★ 2.40 | N/A |
| 52 Week Low | $59.06 | $19.76 |
| 52 Week High | $90.25 | $48.78 |
| Indicator | BC | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.98 | 62.79 |
| Support Level | $74.64 | $37.22 |
| Resistance Level | $76.28 | $47.36 |
| Average True Range (ATR) | 2.98 | 3.14 |
| MACD | 0.18 | 0.94 |
| Stochastic Oscillator | 62.00 | 80.22 |
Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns more than 450 Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.